Benzodiazepines and benzothiazepines derivatives and hbsag peptides binding to annexins, their compositions and use
CA 2335102 A1 · Owner: Innogenetics N.V. · Inventors: Depla, Erik; Maertens, Geert; Moereels, Henri
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to 1,4-benzodiazepines or 1,4-benzothiazepines derivatized with a peptide that can inhibit the interaction between annexin and annexin binding proteins. In particular the present invention relates to , 1,4-benzodiazepines or 1,4-benzothiazepines derivatives that can inhibit the interaction between annexin and viral proteins that bind annexins such as the HBaAg protein of HBV, glycoprotein B of the cytomegalovirus or any annexin binding protein from the influenza virus. These 1,4-benzodiazepines or 1,4benzothiazepines derivates can be used to prevent or treat diseases in which interactions between annexin family members and annexin binding proteins are …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.